X

Trial Profile

Korean College of Rheumatology Biologics and Targeted Therapy Registry

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Rituximab (Primary) ; Secukinumab (Primary) ; Tocilizumab (Primary) ; Ustekinumab (Primary)
Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
Focus Adverse reactions
Acronyms KOBIO; KOBIO-RA

Most Recent Events

24 Apr 2024 Planned number of patients changed from 8000 to 10000.
24 Apr 2024 Planned End Date changed from 30 Jun 2025 to 30 Jun 2030.
24 Apr 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2029.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com